Lineage Cell Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
LCTX$1.08+5.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders Equity
CONSOLIDATED STATEMENTS OFCHANGES IN SHAREHOLDERS’ EQUITY
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Other · Total | ||||||
| Common Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’ | ||||||
| Shares | Amount | Deficit | Deficit | Income / (Loss) | Equity | |
| BALANCE - December 31, 2023 | 174,987 | $451,343 | $(384,856) | $(1,396) | $(3,068) | $62,023 |
| Shares issued through registered direct financings | 45,041 | 29,711 | — | — | — | 29,711 |
| Shares issued through ATM financing | 56 | 70 | — | — | — | 70 |
| Financing related fees | — | (1,685) | — | — | — | (1,685) |
| Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes | 45 | (23) | — | — | — | (23) |
| Shares issued upon exercise of stock options | 287 | 229 | — | — | — | 229 |
| Stock-based compensation | — | 5,077 | — | — | — | 5,077 |
| Unrealized gain on marketable debt securities | — | — | — | — | 3 | 3 |
| Foreign currency translation adjustment, net of tax | — | — | — | — | 189 | 189 |
| Net income (loss) | — | — | (18,609) | 27 | — | (18,582) |
| BALANCE - December 31, 2024 | 220,416 | $484,722 | $(403,465) | $(1,369) | $(2,876) | $77,012 |
| Shares issued through registered direct financing | 7,895 | 3,795 | — | — | — | 3,795 |
| Shares issued through ATM financing | 13,133 | 22,550 | — | — | — | 22,550 |
| Financing related fees | — | (2,092) | — | — | — | (2,092) |
| Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes | 63 | (16) | — | — | — | (16) |
| Shares issued upon exercise of stock options | 1,265 | 1,250 | — | — | — | 1,250 |
| Shares issued upon exercise of warrants | 350 | 319 | — | — | — | 319 |
| Derivative warrant liability reclassified to share capital upon exercise of warrants | — | 187 | — | — | — | 187 |
| Stock-based compensation | — | 4,752 | — | — | — | 4,752 |
| Unrealized gain on marketable debt securities | — | — | — | — | 2 | 2 |
| Foreign currency translation adjustment, net of tax | — | — | — | — | (1,046) | (1,046) |
| Net income (loss) | — | — | (63,533) | 166 | — | (63,367) |
| BALANCE - December 31, 2025 | 243,122 | $515,467 | $(466,998) | $(1,203) | $(3,920) | $43,346 |
.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.